GRPR and neoplasm: Notably, at the 200 pmol peptide dose, the uptake in the GRPR-rich mouse pancreas was significantly reduced (from 206.29 ± 17.35% ID/g to 42.46 ± 1.31% ID/g; p < 0.001), whereas tumor levels remained unaffected.